Predicts median Renal Cell Carcinoma survival, more accurately than the Motzer Criteria.
The Motzer score (which performs similarly with or without the Mekhail extension) is among the most commonly used for mRCC, and is probably best used for selecting patients to enroll in clinical trials. The score retrospectively identified variables associated with survival, which may ultimately help predict outcomes.
We are unaware of validated management algorithms using the score.
The Motzer score (with or without the Mekhail extension) is not known to be accurate for individual survival prediction and should be considered a general guide rather than a concrete predictor.